Drug intelligence / Profile preview

Gegen Huoxue Tongluo liniment

Development stage: Preclinical
Lead developer: The First Affiliated Hospital of Heilongjiang University of Chinese Medicine
Administration: Topical

Overview

Gegen Huoxue Tongluo liniment is a traditional Chinese medicine (TCM) topical preparation formulated as an external liniment. Developed by the First Affiliated Hospital of Heilongjiang University of Chinese Medicine, it is used to treat knee osteoarthritis, rheumatoid arthritis, and knee dysfunction resulting from trauma. In clinical trials, it has been evaluated as part of a combined TCM regimen—alongside oral TCM granules (such as Osteoarthritis granules and Duhuo Sanqi Xiaotong granules) and physical therapy—to improve outcomes and joint function in patients recovering from knee arthroplasty.

Other names: Gegen Huoxue Tongluo Liniment

Targets

AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)

Beyond the preview

Go deeper on Gegen Huoxue Tongluo liniment.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gegen Huoxue Tongluo liniment.

Explore the full profile